Asgard Therapeutics, Sweden
Cristiana Pires is Chief Executive Officer and scientific co-founder of Asgard Therapeutics, a pre-clinical stage company developing in-vivo direct reprogramming approaches for cancer immunotherapy. As CEO, Dr. Pires spearheads Asgard’s mission to pioneer off-the-shelf therapies capable of recreating functional immune cells withing the patient´s body, overcoming the manufacturing and logistic hurdles of traditional cell therapies.
Dr. Pires holds a PharmD from University of Porto and a PhD in cellular reprogramming for regenerative medicine from NOVA Medical School, Portugal. She conducted her postdoctoral studies with Prof. Filipe Pereira at Lund University, Sweden, where she focused on the identification of factors enabling cell fate reprogramming towards dendritic cells for immunotherapy. This groundbreaking work laid the foundation for the establishment of Asgard Therapeutics.
PLENARY VI: THE CLINICAL REALITY AND PROMISE OF CELL AND GENE THERAPIES
Saturday, July 13, 2024
10:00 AM – 11:35 AM CEST
Saturday, July 13, 2024
10:45 AM – 11:05 AM CEST